Sarosdy M F, deVere White R W, Soloway M S, Sheinfeld J, Hudson M A, Schellhammer P F, Jarowenko M V, Adams G, Blumenstein B A
Department of Urology, University of Texas Health Science Center, San Antonio, USA.
J Urol. 1995 Aug;154(2 Pt 1):379-83; discussion 383-4. doi: 10.1097/00005392-199508000-00013.
We compare the Bard BTA (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer.
A prospective, blinded, multicenter trial was performed.
A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was more sensitive than cytology studies in detecting recurrent cancer (p < 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9%.
The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.
我们将巴德膀胱肿瘤抗原（BTA）检测与接受复发性膀胱癌监测性膀胱镜检查患者的尿脱落细胞学检查进行比较。
进行了一项前瞻性、盲法、多中心试验。
共有499例患者接受了1014次膀胱镜检查，其中151例发现肿瘤。在检测复发性癌症方面，膀胱肿瘤抗原检测比细胞学检查更敏感（p<0.001），膀胱肿瘤抗原检测阳性61例，而细胞学检查阳性25例。在健康志愿者和非泌尿外科患者中进行的试验估计膀胱肿瘤抗原检测的特异性为95.9%。
膀胱肿瘤抗原检测是一种简单、快速且廉价的膀胱镜检查辅助手段，其结果与本试验中尿脱落细胞学检查的结果相当或更优。
